<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03081884</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00092595</org_study_id>
    <secondary_id>U01CA113913-11</secondary_id>
    <nct_id>NCT03081884</nct_id>
  </id_info>
  <brief_title>Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease</brief_title>
  <acronym>EDRN-FACBC</acronym>
  <official_title>Validation of FACBC as an Early Indicator of Sub-clinical Metastatic Disease Among High-risk Prostate Cancer Patients With Presumed Localized Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is for patients who have a high risk of metastatic prostate cancer (cancer that&#xD;
      has spread outside of the prostate) who are going to have radical prostatectomy. The&#xD;
      Anti-1-amino-3-[18F]fluorocyclobutyl-1-carboxylic acid (FACBC or Fluciclovine) positron&#xD;
      emission tomography (PET) scan is a new imaging approach that has promising results in&#xD;
      showing progression of cancer. The goal of this study is to determine if FACBC PET imaging&#xD;
      will detect metastatic disease in patients with high risk prostate cancer who have negative&#xD;
      conventional cross-sectional imaging such as computed tomography (CT) and/or magnetic&#xD;
      resonance imaging (MRI), as well as bone scan and/or sodium fluoride PET. FACBC PET imaging&#xD;
      may help detect metastatic prostate cancer in patients with newly diagnosed high risk primary&#xD;
      prostate cancer and potentially improve staging of the cancer. Additionally, the researchers&#xD;
      will compare the FACBC uptake in the prostate with uptake of FACBC detected in metastasis.&#xD;
      They will also analyze and compare the prostate tissue, serum and urine parameters that are&#xD;
      linked to higher rates of FACBC positivity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 50-80% of patients who are considered high-risk after being treated with&#xD;
      definitive radical prostatectomy experience recurrent disease, often because of undetected&#xD;
      extra-prostatic metastatic disease prior to treatment. There is increasing evidence that&#xD;
      performing radical prostatectomy in patients with high-risk disease or locally advanced&#xD;
      disease is feasible and has potential benefits in terms of local control, overall survival,&#xD;
      and quality of life. Thus, improved imaging approaches for early detection of occult&#xD;
      metastatic prostate cancer at the time of presentation could inform a directed treatment&#xD;
      approach that would significantly improve patient outcomes, including use of extended&#xD;
      lymphadenectomy as well as postoperative radiation therapy planning.&#xD;
&#xD;
      Amino acid transport is up-regulated in prostate and other cancers.&#xD;
      Anti-1-amino-3-[18F]fluorocyclobutyl-1-carboxylic acid (FACBC) is a synthetic amino acid&#xD;
      analog positron emission tomography (PET) radiotracer that has demonstrated promising results&#xD;
      in the staging and restaging of prostate carcinoma, with high positive predictive value (PPV)&#xD;
      in the identification of extraprostatic malignancy. Most of the prior studies of FACBC were&#xD;
      in post-primary treatment recurrence, and this proposed trial will be the first comprehensive&#xD;
      study to evaluate FACBC PET in detecting occult metastatic disease at initial diagnosis in&#xD;
      patients with negative or equivocal conventional imaging, with the objective of developing a&#xD;
      more effective primary treatment plan.&#xD;
&#xD;
      The goal of this study is to determine if FACBC PET will detect significant occult metastatic&#xD;
      disease in patients with high risk primary prostate carcinoma who have negative or equivocal&#xD;
      conventional imaging such as CT and/or MRI and bone scan. Participants will have a single&#xD;
      scan prior to surgery for this study. Participants will be followed, through medical record&#xD;
      reviews, for 10 years but no additional procedures related to this study will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All participants will have the same intervention</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cancer Detection Performance of FACBC PET/CT</measure>
    <time_frame>Day 1</time_frame>
    <description>The performance of FACBC PET/CT for diagnosing metastatic cancer was determined by confirming the FACBC PET/CT findings to the histological analysis of the lymph nodes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic Performance of FACBC PET/CT and Conventional Imaging</measure>
    <time_frame>Day 1, Day of surgery</time_frame>
    <description>The diagnostic performance of FACBC PET/CT in the detection of extraprostatic disease is compared to the diagnostic performance of standard imaging, as confirmed with lymph node histology.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>FACBC PET-CT Imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals who have been diagnosed with primary prostate carcinoma and do not have definitive findings of systemic metastasis with conventional imaging will have a whole body FACBC PET-CT scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FACBC PET-CT Imaging</intervention_name>
    <description>Participants will fast for 4 hours to normalize their neutral amino acid levels. One hour prior to the scan, participants will drink up to 450ml of standard oral contrast. Participants will lie on the scanning bed while the bed moves through the PET/CT scanner for the CT portion of the exam. After completion of the CT scan, approximately 10 units of FACBC will be injected for the PET scan portion of the exam. The bed will move through the scanner again and the PET portion of the exam will take 30 minutes. The entire visit will take about two hours.&#xD;
Standard of care procedures include conventional imaging (CT and/or MRI; bone scan and/or NaF PET per institutional standards) and radical prostatectomy with extended pelvic lymph node dissection.</description>
    <arm_group_label>FACBC PET-CT Imaging</arm_group_label>
    <other_name>Fluciclovine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  High-risk prostate cancer patients eligible for standard of care surgery&#xD;
&#xD;
               -  At least clinical T3a disease, and/or Gleasonâ‰¥8, and/or Prostate-Specific Antigen&#xD;
                  (PSA) &gt;20, as per clinical assessment and routine guidelines&#xD;
&#xD;
          -  Undergone standard of care conventional imaging (CT and/or MRI; bone scan and/or&#xD;
             sodium fluoride (NaF) PET)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Definitive findings of systemic metastasis on conventional imaging.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehrdad Alemozaffar</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David M Schuster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Alemozaffar M, Akintayo AA, Abiodun-Ojo OA, Patil D, Saeed F, Huang Y, Osunkoya AO, Goodman MM, Sanda M, Schuster DM. [(18)F]Fluciclovine Positron Emission Tomography/Computerized Tomography for Preoperative Staging in Patients with Intermediate to High Risk Primary Prostate Cancer. J Urol. 2020 Oct;204(4):734-740. doi: 10.1097/JU.0000000000001095. Epub 2020 Apr 29.</citation>
    <PMID>32347780</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 28, 2017</study_first_submitted>
  <study_first_submitted_qc>March 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2017</study_first_posted>
  <results_first_submitted>December 11, 2020</results_first_submitted>
  <results_first_submitted_qc>January 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 25, 2021</results_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>David M Schuster</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>Metastatic cancer</keyword>
  <keyword>Urogenital disorders</keyword>
  <keyword>Oncology</keyword>
  <keyword>Radiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 30, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT03081884/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participant enrollment began March 1, 2017 and all study follow-up was completed by December 31, 2019. Participants were enrolled from the patient population at Emory University Hospital in Atlanta, Georgia.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>FACBC PET-CT Imaging</title>
          <description>Individuals diagnosed with primary prostate carcinoma and without definitive findings of systemic metastasis with conventional imaging, had a whole body FACBC positron emission tomography (PET)-computerized tomography (CT)(PET-CT) scan followed by robotic radical prostatectomy with extended pelvic lymph node dissection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>deferred prostate cancer treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>metastasis managed with systemic therapy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline analysis population includes participants who completed the study.</population>
      <group_list>
        <group group_id="B1">
          <title>FACBC PET-CT Imaging</title>
          <description>Individuals diagnosed with primary prostate carcinoma and without definitive findings of systemic metastasis with conventional imaging, had a whole body FACBC positron emission tomography (PET)-computerized tomography (CT)(PET-CT) scan followed by robotic radical prostatectomy with extended pelvic lymph node dissection.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.7" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of Standard of Care Imaging</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Computerized tomography (CT)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Magnetic resonance imaging (MRI)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cancer Detection Performance of FACBC PET/CT</title>
        <description>The performance of FACBC PET/CT for diagnosing metastatic cancer was determined by confirming the FACBC PET/CT findings to the histological analysis of the lymph nodes.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FACBC PET-CT Imaging</title>
            <description>Individuals diagnosed with primary prostate carcinoma and without definitive findings of systemic metastasis with conventional imaging, had a whole body FACBC PET-CT scan followed by robotic radical prostatectomy with extended pelvic lymph node dissection.</description>
          </group>
        </group_list>
        <measure>
          <title>Cancer Detection Performance of FACBC PET/CT</title>
          <description>The performance of FACBC PET/CT for diagnosing metastatic cancer was determined by confirming the FACBC PET/CT findings to the histological analysis of the lymph nodes.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>True positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>True negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>False positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>False negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diagnostic Performance of FACBC PET/CT and Conventional Imaging</title>
        <description>The diagnostic performance of FACBC PET/CT in the detection of extraprostatic disease is compared to the diagnostic performance of standard imaging, as confirmed with lymph node histology.</description>
        <time_frame>Day 1, Day of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FACBC PET-CT Imaging</title>
            <description>Individuals diagnosed with primary prostate carcinoma and without definitive findings of systemic metastasis with conventional imaging, had a whole body FACBC PET-CT scan followed by robotic radical prostatectomy with extended pelvic lymph node dissection.</description>
          </group>
          <group group_id="O2">
            <title>Conventional Imaging</title>
            <description>Study participants also had conventional imaging (CT or MRI) as part of standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance of FACBC PET/CT and Conventional Imaging</title>
          <description>The diagnostic performance of FACBC PET/CT in the detection of extraprostatic disease is compared to the diagnostic performance of standard imaging, as confirmed with lymph node histology.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3" lower_limit="43.0" upper_limit="68.0"/>
                    <measurement group_id="O2" value="33.3" lower_limit="21.0" upper_limit="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specificity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.8" lower_limit="75.0" upper_limit="94.7"/>
                    <measurement group_id="O2" value="84.1" lower_limit="73.3" upper_limit="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive predictive value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.5" lower_limit="69.2" upper_limit="93.3"/>
                    <measurement group_id="O2" value="72.2" lower_limit="55.6" upper_limit="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative predictive value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8" lower_limit="47.8" upper_limit="73.7"/>
                    <measurement group_id="O2" value="51.2" lower_limit="40.0" upper_limit="63.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Accuracy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5" lower_limit="59.4" upper_limit="78.1"/>
                    <measurement group_id="O2" value="56.3" lower_limit="47.2" upper_limit="65.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were documented beginning at the time when the radiotracer was administered and ending 7 days after administration.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FACBC PET-CT Imaging</title>
          <description>Individuals diagnosed with primary prostate carcinoma and without definitive findings of systemic metastasis with conventional imaging, had a whole body FACBC positron emission tomography (PET)-computerized tomography (CT)(PET-CT) scan followed by robotic radical prostatectomy with extended pelvic lymph node dissection.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David M. Schuster, MD</name_or_title>
      <organization>Emory University</organization>
      <phone>404-712-4859</phone>
      <email>dschust@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

